Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Athyros VG, et al. Curr Med Res Opin. 2011 Aug;27(8):1659-68. doi: 10.1185/03007995.2011.595782. Epub 2011 Jun 30. Curr Med Res Opin. 2011. PMID: 21714711 Clinical Trial.
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Athyros VG, et al. Among authors: ganotakis e. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57. doi: 10.2174/157016111797484080. Curr Vasc Pharmacol. 2011. PMID: 21476961 Clinical Trial.
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.
Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Athyros VG, et al. Among authors: ganotakis es. Arch Med Sci. 2011 Oct;7(5):796-805. doi: 10.5114/aoms.2011.25554. Epub 2011 Nov 8. Arch Med Sci. 2011. PMID: 22291824 Free PMC article.
Subclinical hypothyroidism and vascular risk: an update.
Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Lioudaki E, et al. Among authors: ganotakis es. Hormones (Athens). 2013 Oct-Dec;12(4):495-506. doi: 10.14310/horm.2002.1437. Hormones (Athens). 2013. PMID: 24457397 Free article. Review.
Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome.
Chimonas T, Athyros VG, Ganotakis E, Nicolaou V, Panagiotakos DB, Mikhailidis DP, Elisaf M; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Chimonas T, et al. Among authors: ganotakis e. Angiology. 2010 Feb-Mar;61(1):49-57. doi: 10.1177/0003319709351873. Angiology. 2010. PMID: 20034959
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Athyros VG, et al. Among authors: ganotakis e. Angiology. 2012 Jul;63(5):358-66. doi: 10.1177/0003319711421341. Epub 2011 Oct 17. Angiology. 2012. PMID: 22007026 Clinical Trial.
Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Koutroubakis IE, et al. Among authors: ganotakis e. Eur J Gastroenterol Hepatol. 2009 Mar;21(3):283-8. doi: 10.1097/MEG.0b013e328325d42b. Eur J Gastroenterol Hepatol. 2009. PMID: 19279474
Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.
Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, Vardas E, Vrentzos G, Ganotakis E, Mouzas IA, Gravanis A, Emmanouel D, Kouroumalis EA. Koutroubakis IE, et al. Among authors: ganotakis e. Dig Dis Sci. 2000 Dec;45(12):2347-51. doi: 10.1023/a:1005583606647. Dig Dis Sci. 2000. PMID: 11258554
97 results